Checkpoint Inhibitors: Effective in NSCLC Patients With Pre-existing Autoimmune Disease?

Leggi l'articolo originale


The results, described by an expert as “very interesting” and a “a bit surprising,” focused on the impact of autoimmune antibodies on anti–PD-1 therapy.

Lascia un commento